Rondecabtagene autoleucel

朗迪卡基奥仑赛

Report date: 2026/04/16 20:00:17

Base Information

Drug NameRondecabtagene autoleucel
Drug Alias Nameronde-celIMPT-314LYL-314LYL314
ClassificationCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Lentiviral vectorCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy > Dual-target CAR-T cell therapy +[5] 
Mechanisms of ActionAnti-CD19Anti-CD20T lymphocyte replacements
TargetsB-lymphocyte antigen CD19B-lymphocyte antigen CD20
Therapy Area/IndicationsLarge B Cell LymphomaLymphoma, Large B-Cell, DiffuseLymphoma, B-Cell +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesAustralia
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesImmPACT Bio USA Inc
China Registration ClassN/A

Develop Information

Active CompaniesLyell Immunopharma Inc
Inactive CompaniesN/A
Active IndicationsLarge B Cell LymphomaLymphoma, Large B-Cell, DiffuseLymphoma, B-Cell +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A